SCHEMBL23723952

SCHEMBL23723952

Cc1cc(OC(=O)C(C)N)no1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TMPRSS15 P98073 1/20 0.47
RAB9A P51151 6/20 0.39
NPC1 O15118 5/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
KLK7 P49862 2/20 0.36
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36
HTT P42858 1/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
EGFR P00533 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6632393 0.79 TMPRSS15 (0.55) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL9844093 0.77 TMPRSS15 (0.47) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL27361867 0.77 RAB9A (0.49) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL875579 0.77 TMPRSS15 (0.49) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL8305554 0.75 TMPRSS15 (0.48) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL19520914 0.72 TMPRSS15 (0.49) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL27952188 0.71 TMPRSS15 (0.45) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL9531781 0.69 NPC1 (0.48) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL10200350 0.69 TRPM8 (0.45) TMPRSS15RAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL22660992 0.68 PIK3CD (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230126157-A1 MIRNA-485 INHIBITOR FOR GENE UPREGULATION BIORCHESTRA CO., LTD. (KR) 2023-04-27 US disclosed
CN-115666655-A Designer extracellular vesicles for treatment of excitotoxicity 俄亥俄州立创新基金会 2023-01-31 CN disclosed
EP-4100067-A1 MIRNA-485 INHIBITOR FOR GENE UPREGULATION Biorchestra Co., Ltd. (KR) 2022-12-14 EP disclosed
WO-2022003609-A1 SNP DIAGNOSTIC METHODS BIORCHESTRA CO., LTD. (KR) 2022-01-06 WO disclosed
WO-2021156831-A1 MIRNA-485 INHIBITOR FOR GENE UPREGULATION BIORCHESTRA CO., LTD. (KR) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230126157-A1 MIRNA-485 INHIBITOR FOR GENE UPREGULATION NRP1, SORT1, NR4A3 TMPRSS15 3188/4885RAB9A 2284/4885NPC1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.